I’ve earned my physicians’ trust.
Illumina has earned mine.
Our industry leading next-generation sequencing (NGS) and microarray technologies deliver fast, accurate information that can guide choices and transform lives at multiple touchpoints along the reproductive and genetic health care journey.
If you’re a current customer or visitor from Verinata or BlueGenome, please login here.
Preimplantation genetic screening (PGS) has been demonstrated to improve in vitro fertilization (IVF) success rates by selecting the most viable embryos for transfer and implantation.
Preimplantation genetic diagnosis (PGD) can be used to screen embryos where there is a risk of severe genetic disorders being inherited from parents.
Noninvasive prenatal testing (NIPT) delivers early, safe, and reliable answers about the chromosomal health of a developing fetus—minimizing the need for riskier invasive procedures.
Illumina provides a number of other solutions that screen for and detect important genetic conditions and inherited diseases
Cystic Fibrosis Testing Recognizes inherited disease carrier status—providing answers and guidance for prospective parents concerned about passing on genes linked to genetic disorders to their children. Learn about Cystic Fibrosis Testing
Inherited Condition Screening with NGS Detects undiagnosed inherited conditions providing reliable answers and peace of mind for all involved. Learn about Inherited Condition Screening with NGS
Our advanced genomic solutions are setting new standards of success in reproductive and genetic health, but the data tell only one side of the story. Enhanced patient and provider peace of mind tell the other.
Higher Rate of Pregnancy With PGS
In one study, pregnancy rates improved significantly when embryos selected for transfer were screened for normal chromosome numbers compared to conventional morphology methods.1
The New England Journal of Medicine published study finds verifi Prenatal Test performed by the Illumina clinical lab, achieves 10x higher positive predictive value vs. current standard of care.
Cystic Fibrosis Carrier Screening
Highly accurate and reproducible results with ≥ 99.7% overall agreement
for all reported positions and variants for the carrier screening and
To learn more about how our innovative genomic solutions can make a life-changing difference in your clinical lab, click on the subjects of interest below.